Zura Bio Ltd
ZURA3.440USD
-0.040-1.15%
交易中 （美东）报价延迟15分钟
235.21M总市值
亏损市盈率 TTM
关于 Zura Bio Ltd 公司
Zura Bio Limited 是一家临床阶段、多资产免疫学公司，致力于开发用于自身免疫和炎症疾病的新型双通路抗体。该公司正在开发三种资产，这些资产已完成 I/Ib 期研究并准备进行 II 期研究。该公司正在开发一系列治疗适应症的药物，包括替布珠单抗 (ZB-106)、ZB-168 和 torudokimab (ZB-880)，旨在证明它们在自身免疫和炎症疾病（包括系统性硬化症和其他未满足需求的新适应症）中的疗效、安全性和给药便利性。替布珠单抗 (ZB-106) 是一种 IgG-scFv 双特异性双拮抗剂抗体，由 TALTZ (ixekizumab) 和 tabalumab 融合而成，可中和 IL-17A 和 BAFF。 ZB-168 是一种全人源高亲和力单克隆抗体，可结合并中和 IL-7 受体链 (IL-7R) α。Torudokimab (ZB-880) 是一种全人源高亲和力单克隆抗体，可中和 IL-33，从而预防 ST2 依赖性和 ST2 非依赖性炎症。
Zura Bio Ltd简介
公司代码ZURA
公司名称Zura Bio Ltd
上市日期Jul 16, 2021
CEOMr. Robert Lisicki
员工数量30
证券类型Ordinary Share
年结日Jul 16
公司地址4225 Executive Square
城市LA JOLLA
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编92037
电话18582470520
网址https://zurabio.com/
公司代码ZURA
上市日期Jul 16, 2021
CEOMr. Robert Lisicki
Zura Bio Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Someit Sidhu, M.D.
Dr. Someit Sidhu, M.D.
Director
Director
3.99M
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
652.39K
+62.13%
Dr. Kiran Nistala
Dr. Kiran Nistala
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
3.19K
--
Mr. Eric Hyllengren
Mr. Eric Hyllengren
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Dan Becker
Dr. Dan Becker
Independent Director
Independent Director
--
--
Dr. Neil Graham, M.D.
Dr. Neil Graham, M.D.
Independent Director
Independent Director
--
--
Mr. Gary Whale
Mr. Gary Whale
Chief Technology Officer
Chief Technology Officer
--
--
Ms. Kim Davis
Ms. Kim Davis
Interim Chief Executive Officer, Interim Principal Executive Officer, Chief Operating Officer, Chief Legal Officer and Corporate Secretary
Interim Chief Executive Officer, Interim Principal Executive Officer, Chief Operating Officer, Chief Legal Officer and Corporate Secretary
--
--
Ms. Jennifer Jarrett
Ms. Jennifer Jarrett
Independent Director
Independent Director
--
--
Mr. Sandeep Kulkarni, M.D.
Mr. Sandeep Kulkarni, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Someit Sidhu, M.D.
Dr. Someit Sidhu, M.D.
Director
Director
3.99M
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
652.39K
+62.13%
Dr. Kiran Nistala
Dr. Kiran Nistala
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
3.19K
--
Mr. Eric Hyllengren
Mr. Eric Hyllengren
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Dan Becker
Dr. Dan Becker
Independent Director
Independent Director
--
--
Dr. Neil Graham, M.D.
Dr. Neil Graham, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Hana Immunotherapeutics LLC
8.31%
Suvretta Capital Management, LLC
7.48%
J.P. Morgan Securities LLC
7.16%
VR Adviser, LLC
7.12%
Access Industries, Inc.
7.00%
其他
62.92%
持股股东
持股股东
占比
Hana Immunotherapeutics LLC
8.31%
Suvretta Capital Management, LLC
7.48%
J.P. Morgan Securities LLC
7.16%
VR Adviser, LLC
7.12%
Access Industries, Inc.
7.00%
其他
62.92%
股东类型
持股股东
占比
Hedge Fund
30.73%
Corporation
20.25%
Research Firm
8.36%
Individual Investor
7.49%
Venture Capital
7.12%
Investment Advisor
3.40%
Investment Advisor/Hedge Fund
1.46%
Family Office
0.02%
其他
21.16%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
170
33.21M
51.07%
-18.88M
2025Q2
175
61.14M
98.81%
-5.26M
2025Q1
176
62.77M
102.70%
-1.15M
2024Q4
196
61.97M
94.80%
-4.48M
2024Q3
181
65.04M
110.26%
-425.40K
2024Q2
164
62.71M
112.19%
-1.03M
2024Q1
154
45.76M
105.85%
-6.22M
2023Q4
146
45.65M
115.47%
+3.33M
2023Q3
134
44.62M
116.27%
+3.13M
2023Q2
116
43.65M
115.88%
+17.62M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Hana Immunotherapeutics LLC
5.40M
8.31%
--
--
Apr 01, 2025
Suvretta Capital Management, LLC
4.86M
7.48%
--
--
Jun 30, 2025
J.P. Morgan Securities LLC
4.66M
7.16%
+2.08M
+80.44%
Jun 30, 2025
VR Adviser, LLC
4.63M
7.12%
-391.95K
-7.80%
Jun 30, 2025
Access Industries, Inc.
4.55M
7%
+500.00K
+12.34%
May 21, 2025
Sidhu (Someit)
3.99M
6.14%
--
--
Apr 01, 2025
Great Point Partners, LLC
3.17M
4.88%
--
--
Jun 30, 2025
Pfizer Inc
2.97M
4.57%
--
--
Jun 30, 2025
Braidwell LP
2.47M
3.8%
--
--
Jun 30, 2025
Point72 Asset Management, L.P.
2.35M
3.61%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
iShares Micro-Cap ETF
0.03%
Global X Russell 2000 ETF
0%
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.03%
Global X Russell 2000 ETF
占比0%
Invesco Raymond James SB-1 Equity ETF
占比0%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0%
Schwab U.S. Small-Cap ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
Proshares Ultra Russell 2000
占比0%
iShares Russell 2000 Growth ETF
占比0%
ProShares Hedge Replication ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
